Role of Alprazolam in the Management of Acute Coronary Syndrome

• Status: Recruiting
• Trial end date: 2022-02-20
• Target enrollment: 0
• Participant gender: All

Summary

Cardiovascular disease has always been one of the most concerning ailments of all times considering mortality. On one end due to the emergence of pharmaceutical technology, there is a reduction in mortality, on the other hand owing to a sedentary lifestyle the incidence of this disease is increasing. Hence leading to up slopping trend in cardiovascular prevalence. Acute coronary syndrome is one of the most deadly and acute presentations of cardiology requiring immediate intervention to dampen the frequency of complications. One of the fundamental goals in the treatment of ACS is to lower the heart rate so that load on myocardial tissue can be reduced. In order to do so, we already have multiple options like beta-blockers, calcium channel blockers, and new generation ivabradine (not affecting blood pressure unlike others).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sohaib Ashraf
• Treatments: Alprazolam

Criteria

Inclusion Criteria:

Systolic BP>100mm Hg Age between 18-80 years Sinus Rhythm

Exclusion Criteria:

• Cardiogenic Shock / Hypotension

• Known Asthma/COPD

• Bradycardia (HR < 60)

• Already on Beta blockers/ Anxiolytics

• Sick sinus syndrome

• Second or third-degree heart block (in the absence of pacemaker)

• Decompensated heart failure

• With documented hypersensitivity to the drug or components

• Valvular Heart Diseases

• Congenital Heart Diseases

• Status post CABG

• Any co-morbidities except Diabetes Mellitus and Hypertension